Trial · NCT02207621

Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular Hypertension

NCT02207621, Phase 3, Completed, Aerie Pharmaceuticals; results first posted 2018-04-06

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular Hypertension. Trials, record NCT02207621. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02207621

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular Hypertension
NCT number: NCT02207621
Status: Completed
Phases: Phase 3
Enrollment: 756 participants, actual
Lead sponsor: Aerie Pharmaceuticals
Conditions: Ocular Hypertension, Open-angle Glaucoma
Interventions: AR-13324 Ophthalmic Solution 0.02%, Timolol maleate Ophthalmic Solution 0.5% BID, Placebo, AR-13324 Ophthalmic Solution 0.02% BID
First posted: 2014-08-04
Last updated: 2018-04-06
Results first posted: 2018-04-06

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Intraocular Pressure (IOP)	3 months	The primary efficacy outcome is mean intraocular pressure (IOP)
Secondary	Extent of Exposure	12 Months	Exposure to study medication in days for all treatment groups

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Intraocular Pressure (IOP)	3 months	The Per Protocol (PP) population includes all subjects who did not have a major protocol violation likely to seriously affect the primary outcome of the study. This is the primary population for efficacy analyses.	mmHg	MEAN
SECONDARY	Extent of Exposure	12 Months	The Safety Population included all randomized subjects who received at least 1 dose of study medication and was used to summarize safety variables. The safety population summarized subjects as treated for purpose of analysis. One (1) subject did not receive study drug as randomized, shown in the Participant Flow	days	MEAN

Source ClinicalTrials.gov

Results by group39

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Intraocular Pressure (IOP)	AR-13324 Ophthalmic Solution 0.02% & Placebo	Day 1, 0800 hours	23.51	Standard Deviation 1.654	mmHg
Intraocular Pressure (IOP)	Timolol Maleate Ophthalmic Solution 0.5% BID	Day 1, 0800 hours	23.45	Standard Deviation 1.601	mmHg
Intraocular Pressure (IOP)	AR-13324 Ophthalmic Solution 0.02% BID	Day 1, 0800 hours	23.50	Standard Deviation 1.671	mmHg
Intraocular Pressure (IOP)	AR-13324 Ophthalmic Solution 0.02% & Placebo	Day 1, 1000 hours	22.31	Standard Deviation 2.131	mmHg
Intraocular Pressure (IOP)	Timolol Maleate Ophthalmic Solution 0.5% BID	Day 1, 1000 hours	22.18	Standard Deviation 2.089	mmHg
Intraocular Pressure (IOP)	AR-13324 Ophthalmic Solution 0.02% BID	Day 1, 1000 hours	22.26	Standard Deviation 2.103	mmHg
Intraocular Pressure (IOP)	AR-13324 Ophthalmic Solution 0.02% & Placebo	Day 1, 1600 hours	21.56	Standard Deviation 2.338	mmHg
Intraocular Pressure (IOP)	Timolol Maleate Ophthalmic Solution 0.5% BID	Day 1, 1600 hours	21.61	Standard Deviation 2.369	mmHg
Intraocular Pressure (IOP)	AR-13324 Ophthalmic Solution 0.02% BID	Day 1, 1600 hours	21.49	Standard Deviation 2.279	mmHg
Intraocular Pressure (IOP)	AR-13324 Ophthalmic Solution 0.02% & Placebo	Day 15, 0800 hours	19.01	Standard Deviation 2.979	mmHg

1 to 10 of 39Source ClinicalTrials.gov

See all 39 results by group

Participant flow9

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	AR-13324 Ophthalmic Solution 0.02% & Placebo	251
Overall Study	STARTED	Timolol Maleate Ophthalmic Solution 0.5% BID	251
Overall Study	STARTED	AR-13324 Ophthalmic Solution 0.02% BID	254
Overall Study	COMPLETED	AR-13324 Ophthalmic Solution 0.02% & Placebo	146
Overall Study	COMPLETED	Timolol Maleate Ophthalmic Solution 0.5% BID	204
Overall Study	COMPLETED	AR-13324 Ophthalmic Solution 0.02% BID	86
Overall Study	NOT COMPLETED	AR-13324 Ophthalmic Solution 0.02% & Placebo	105
Overall Study	NOT COMPLETED	Timolol Maleate Ophthalmic Solution 0.5% BID	47
Overall Study	NOT COMPLETED	AR-13324 Ophthalmic Solution 0.02% BID	168

Source ClinicalTrials.gov

Adverse events168

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Conjunctival Hyperaemia	Eye disorders	AR-13324 Ophthalmic Solution 0.02% & Placebo	152	251
other	Conjunctival Hyperaemia	Eye disorders	Timolol Maleate Ophthalmic Solution 0.5% BID	35	251
other	Conjunctival Hyperaemia	Eye disorders	AR-13324 Ophthalmic Solution 0.02% BID	168	253
other	Cornea Verticillata	Eye disorders	AR-13324 Ophthalmic Solution 0.02% & Placebo	64	251
other	Cornea Verticillata	Eye disorders	Timolol Maleate Ophthalmic Solution 0.5% BID	2	251
other	Cornea Verticillata	Eye disorders	AR-13324 Ophthalmic Solution 0.02% BID	64	253
other	Conjunctival Haemorrhage	Eye disorders	AR-13324 Ophthalmic Solution 0.02% & Placebo	49	251
other	Conjunctival Haemorrhage	Eye disorders	Timolol Maleate Ophthalmic Solution 0.5% BID	2	251
other	Conjunctival Haemorrhage	Eye disorders	AR-13324 Ophthalmic Solution 0.02% BID	49	253
other	Vision Blurred	Eye disorders	AR-13324 Ophthalmic Solution 0.02% & Placebo	27	251

1 to 10 of 168Source ClinicalTrials.gov

See all 168 adverse events

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	AR-13324 Ophthalmic Solution 0.02% & Placebo	2	251
Total, all-cause mortality	Timolol Maleate Ophthalmic Solution 0.5% BID	0	251
Total, all-cause mortality	AR-13324 Ophthalmic Solution 0.02% BID	0	253
Total, other adverse events	AR-13324 Ophthalmic Solution 0.02% & Placebo	198	251
Total, other adverse events	Timolol Maleate Ophthalmic Solution 0.5% BID	96	251
Total, other adverse events	AR-13324 Ophthalmic Solution 0.02% BID	213	253
Total, serious adverse events	AR-13324 Ophthalmic Solution 0.02% & Placebo	17	251
Total, serious adverse events	Timolol Maleate Ophthalmic Solution 0.5% BID	12	251
Total, serious adverse events	AR-13324 Ophthalmic Solution 0.02% BID	7	253

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
33250082	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02207621

GET https://conductscience.org/api/trials/v1/NCT02207621/results?page=2

API reference For AI assistants